Glenmark inks licensing pact with Jiangsu Alphamab, 3D Medicines for cancer drug

By

-

10 months ago

Glenmark Pharmaceuticals Ltd announced that its subsidiary, Glenmark Specialty S A (GSSA), has entered into a license agreement with Jiangsu Alphamab Biopharmaceuticals Co and 3D Medicines (Beijing) Co Ltd for KN035 (Envafolimab), a cancer treatment drug. Under the agreement, Glenmark gains the license for KN035 (Envafolimab) in various regions, including India, Asia Pacific, the Middle East, Africa, Russia, CIS, and Latin America.

Read The Rest at :

Economic Times

Topics:

Glenmark Pharmaceuticals

license agreement

Jiangsu Alphamab

3D Medicines

cancer drug

Asia Pacific

Africa

Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.